OICR12694 (TFA)

• UNSPSC Description:

  OICR12694 (JNJ-65234637) TFA is an orally active inhibitor of B cell lymphoma 6 (BCL6)[1].

• Target Antigen:

  Bcl-2 Family

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/oicr12694-tfa.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1C2=C(N=C3N1CCC3)N(CC(NC4=C(Cl)C(F)=NC(N5[C@H](CN(CC5)C)C)=C4)=O)C=C2C6=CC(C(N)=O)=C(C(F)=C6F)O.O=C(O)C(F)(F)F.[x]

• References & Citations:

  [1]Mamai A, et al. Discovery of OICR12694: A Novel, Potent, Selective, and Orally Bioavailable BCL6 BTB Inhibitor. ACS Med Chem Lett. 2023 Jan 12;14(2):199-210.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2360625-98-3